Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay

Oleg A. Volkov, Casey C. Cosner, Anthony J. Brockway, Martin Kramer, Michael Booker, Shihua Zhong, Ariel Ketcherside, Shuguang Wei, Jamie Longgood, Melissa McCoy, Thomas E. Richardson, Stephen A. Wring, Michael Peel, Jeffrey D. Klinger, Bruce A. Posner, Jef K. De Brabander, Margaret A. Phillips

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Human African trypanosomiasis (HAT) is a fatal infectious disease caused by the eukaryotic pathogen Trypanosoma brucei (Tb). Available treatments are difficult to administer and have significant safety issues. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the parasite polyamine biosynthetic pathway. Previous attempts to develop TbAdoMetDC inhibitors into anti-HAT therapies failed due to poor brain exposure. Here, we describe a large screening campaign of two small-molecule libraries (∼400,000 compounds) employing a new high-throughput (∼7 s per sample) mass spectrometry-based assay for AdoMetDC activity. As a result of primary screening, followed by hit confirmation and validation, we identified 13 new classes of reversible TbAdoMetDC inhibitors with low-micromolar potency (IC50) against both TbAdoMetDC and T. brucei parasite cells. The majority of these compounds were >10-fold selective against the human enzyme. Importantly, compounds from four classes demonstrated high propensity to cross the blood-brain barrier in a cell monolayer assay. Biochemical analysis demonstrated that compounds from eight classes inhibited intracellular TbAdoMetDC in the parasite, although evidence for a secondary off-target component was also present. The discovery of several new TbAdoMetDC inhibitor chemotypes provides new hits for lead optimization programs aimed to deliver a novel treatment for HAT.

Original languageEnglish (US)
Pages (from-to)512-526
Number of pages15
JournalACS Infectious Diseases
Volume3
Issue number7
DOIs
StatePublished - Jul 14 2017

Fingerprint

Adenosylmethionine Decarboxylase
Trypanosoma brucei brucei
African Trypanosomiasis
Mass Spectrometry
Parasites
Small Molecule Libraries
Biosynthetic Pathways
Polyamines
Enzymes
Blood-Brain Barrier
Inhibitory Concentration 50
Communicable Diseases
Safety
Brain

Keywords

  • AdoMetDC
  • high-throughput screening
  • human African trypanosomiasis
  • mass spectrometry
  • Trypanosoma brucei

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay. / Volkov, Oleg A.; Cosner, Casey C.; Brockway, Anthony J.; Kramer, Martin; Booker, Michael; Zhong, Shihua; Ketcherside, Ariel; Wei, Shuguang; Longgood, Jamie; McCoy, Melissa; Richardson, Thomas E.; Wring, Stephen A.; Peel, Michael; Klinger, Jeffrey D.; Posner, Bruce A.; De Brabander, Jef K.; Phillips, Margaret A.

In: ACS Infectious Diseases, Vol. 3, No. 7, 14.07.2017, p. 512-526.

Research output: Contribution to journalArticle

Volkov, OA, Cosner, CC, Brockway, AJ, Kramer, M, Booker, M, Zhong, S, Ketcherside, A, Wei, S, Longgood, J, McCoy, M, Richardson, TE, Wring, SA, Peel, M, Klinger, JD, Posner, BA, De Brabander, JK & Phillips, MA 2017, 'Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay', ACS Infectious Diseases, vol. 3, no. 7, pp. 512-526. https://doi.org/10.1021/acsinfecdis.7b00022
Volkov, Oleg A. ; Cosner, Casey C. ; Brockway, Anthony J. ; Kramer, Martin ; Booker, Michael ; Zhong, Shihua ; Ketcherside, Ariel ; Wei, Shuguang ; Longgood, Jamie ; McCoy, Melissa ; Richardson, Thomas E. ; Wring, Stephen A. ; Peel, Michael ; Klinger, Jeffrey D. ; Posner, Bruce A. ; De Brabander, Jef K. ; Phillips, Margaret A. / Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay. In: ACS Infectious Diseases. 2017 ; Vol. 3, No. 7. pp. 512-526.
@article{199e41c5c5844b62a487a2df83b1a142,
title = "Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay",
abstract = "Human African trypanosomiasis (HAT) is a fatal infectious disease caused by the eukaryotic pathogen Trypanosoma brucei (Tb). Available treatments are difficult to administer and have significant safety issues. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the parasite polyamine biosynthetic pathway. Previous attempts to develop TbAdoMetDC inhibitors into anti-HAT therapies failed due to poor brain exposure. Here, we describe a large screening campaign of two small-molecule libraries (∼400,000 compounds) employing a new high-throughput (∼7 s per sample) mass spectrometry-based assay for AdoMetDC activity. As a result of primary screening, followed by hit confirmation and validation, we identified 13 new classes of reversible TbAdoMetDC inhibitors with low-micromolar potency (IC50) against both TbAdoMetDC and T. brucei parasite cells. The majority of these compounds were >10-fold selective against the human enzyme. Importantly, compounds from four classes demonstrated high propensity to cross the blood-brain barrier in a cell monolayer assay. Biochemical analysis demonstrated that compounds from eight classes inhibited intracellular TbAdoMetDC in the parasite, although evidence for a secondary off-target component was also present. The discovery of several new TbAdoMetDC inhibitor chemotypes provides new hits for lead optimization programs aimed to deliver a novel treatment for HAT.",
keywords = "AdoMetDC, high-throughput screening, human African trypanosomiasis, mass spectrometry, Trypanosoma brucei",
author = "Volkov, {Oleg A.} and Cosner, {Casey C.} and Brockway, {Anthony J.} and Martin Kramer and Michael Booker and Shihua Zhong and Ariel Ketcherside and Shuguang Wei and Jamie Longgood and Melissa McCoy and Richardson, {Thomas E.} and Wring, {Stephen A.} and Michael Peel and Klinger, {Jeffrey D.} and Posner, {Bruce A.} and {De Brabander}, {Jef K.} and Phillips, {Margaret A.}",
year = "2017",
month = "7",
day = "14",
doi = "10.1021/acsinfecdis.7b00022",
language = "English (US)",
volume = "3",
pages = "512--526",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay

AU - Volkov, Oleg A.

AU - Cosner, Casey C.

AU - Brockway, Anthony J.

AU - Kramer, Martin

AU - Booker, Michael

AU - Zhong, Shihua

AU - Ketcherside, Ariel

AU - Wei, Shuguang

AU - Longgood, Jamie

AU - McCoy, Melissa

AU - Richardson, Thomas E.

AU - Wring, Stephen A.

AU - Peel, Michael

AU - Klinger, Jeffrey D.

AU - Posner, Bruce A.

AU - De Brabander, Jef K.

AU - Phillips, Margaret A.

PY - 2017/7/14

Y1 - 2017/7/14

N2 - Human African trypanosomiasis (HAT) is a fatal infectious disease caused by the eukaryotic pathogen Trypanosoma brucei (Tb). Available treatments are difficult to administer and have significant safety issues. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the parasite polyamine biosynthetic pathway. Previous attempts to develop TbAdoMetDC inhibitors into anti-HAT therapies failed due to poor brain exposure. Here, we describe a large screening campaign of two small-molecule libraries (∼400,000 compounds) employing a new high-throughput (∼7 s per sample) mass spectrometry-based assay for AdoMetDC activity. As a result of primary screening, followed by hit confirmation and validation, we identified 13 new classes of reversible TbAdoMetDC inhibitors with low-micromolar potency (IC50) against both TbAdoMetDC and T. brucei parasite cells. The majority of these compounds were >10-fold selective against the human enzyme. Importantly, compounds from four classes demonstrated high propensity to cross the blood-brain barrier in a cell monolayer assay. Biochemical analysis demonstrated that compounds from eight classes inhibited intracellular TbAdoMetDC in the parasite, although evidence for a secondary off-target component was also present. The discovery of several new TbAdoMetDC inhibitor chemotypes provides new hits for lead optimization programs aimed to deliver a novel treatment for HAT.

AB - Human African trypanosomiasis (HAT) is a fatal infectious disease caused by the eukaryotic pathogen Trypanosoma brucei (Tb). Available treatments are difficult to administer and have significant safety issues. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the parasite polyamine biosynthetic pathway. Previous attempts to develop TbAdoMetDC inhibitors into anti-HAT therapies failed due to poor brain exposure. Here, we describe a large screening campaign of two small-molecule libraries (∼400,000 compounds) employing a new high-throughput (∼7 s per sample) mass spectrometry-based assay for AdoMetDC activity. As a result of primary screening, followed by hit confirmation and validation, we identified 13 new classes of reversible TbAdoMetDC inhibitors with low-micromolar potency (IC50) against both TbAdoMetDC and T. brucei parasite cells. The majority of these compounds were >10-fold selective against the human enzyme. Importantly, compounds from four classes demonstrated high propensity to cross the blood-brain barrier in a cell monolayer assay. Biochemical analysis demonstrated that compounds from eight classes inhibited intracellular TbAdoMetDC in the parasite, although evidence for a secondary off-target component was also present. The discovery of several new TbAdoMetDC inhibitor chemotypes provides new hits for lead optimization programs aimed to deliver a novel treatment for HAT.

KW - AdoMetDC

KW - high-throughput screening

KW - human African trypanosomiasis

KW - mass spectrometry

KW - Trypanosoma brucei

UR - http://www.scopus.com/inward/record.url?scp=85023746447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023746447&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.7b00022

DO - 10.1021/acsinfecdis.7b00022

M3 - Article

C2 - 28350440

AN - SCOPUS:85023746447

VL - 3

SP - 512

EP - 526

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

IS - 7

ER -